北方药学
北方藥學
북방약학
JOURNAL OF NORTH PHARMACY
2015年
6期
111-112
,共2页
肠易激综合征%黛力新%得舒特%美常安
腸易激綜閤徵%黛力新%得舒特%美常安
장역격종합정%대력신%득서특%미상안
irritable bowel syndrome%Dicetel%Deanxit%Medilac-S
目的:探讨得舒特联合黛力新、美常安治疗肠易激综合征(IBS)的疗效。方法:收集2012年1月~2014年12月在我院诊断为符合IBS患者457例,随机分为黛力新联合得舒特、美常安(观察组)患者154例,得舒特联合美常安组(对照1组)患者151例及黛力新联合得舒特组(对照2组)患者152例;治疗2周后对疗效进行评估。结果:观察组的疗效优于对照1组及对照2组,差异均具有统计学意义(P<0.05),对照1组和对照2组的疗效差别不大(P>0.05)。治疗后观察组临床症状与对照组的差异有统计学意义(P<0.05)。结论:得舒特联合黛力新、美常安治疗肠易激综合征比仅其中两者联用更为有效。
目的:探討得舒特聯閤黛力新、美常安治療腸易激綜閤徵(IBS)的療效。方法:收集2012年1月~2014年12月在我院診斷為符閤IBS患者457例,隨機分為黛力新聯閤得舒特、美常安(觀察組)患者154例,得舒特聯閤美常安組(對照1組)患者151例及黛力新聯閤得舒特組(對照2組)患者152例;治療2週後對療效進行評估。結果:觀察組的療效優于對照1組及對照2組,差異均具有統計學意義(P<0.05),對照1組和對照2組的療效差彆不大(P>0.05)。治療後觀察組臨床癥狀與對照組的差異有統計學意義(P<0.05)。結論:得舒特聯閤黛力新、美常安治療腸易激綜閤徵比僅其中兩者聯用更為有效。
목적:탐토득서특연합대력신、미상안치료장역격종합정(IBS)적료효。방법:수집2012년1월~2014년12월재아원진단위부합IBS환자457례,수궤분위대력신연합득서특、미상안(관찰조)환자154례,득서특연합미상안조(대조1조)환자151례급대력신연합득서특조(대조2조)환자152례;치료2주후대료효진행평고。결과:관찰조적료효우우대조1조급대조2조,차이균구유통계학의의(P<0.05),대조1조화대조2조적료효차별불대(P>0.05)。치료후관찰조림상증상여대조조적차이유통계학의의(P<0.05)。결론:득서특연합대력신、미상안치료장역격종합정비부기중량자련용경위유효。
Objective To investigate and analysis the curative effect of Deanxit unite Dicetel and Medilac-S to treat irritable bowel syndrome. Methods We collected 427 cases of patients for irritable bowel syndrome from January 2013 to December 2014 in our hospital,were randomly divided into three groups. The treatment group(n=154):Deanxit unite Dicetel and Medilac-S;the control group 1 (n=151): Dicetel unite Medilac-S; the control group 2 (n=152): Deanxit unite Dicetel. after 2 weeks of treatment, evaluating the therapeutic effect. Results The efficacy of the treatment group is higher than the other two in the control group,(P<0.05), control group 1 and control group 2 have little difference in efficacy. There are differences in clinical symptoms between treatment group and control group (P<0.05). Conclusion Dicetel unite Deanxit and Medilac-S for treating diarrhea irritable bowel syndrome is more effective than the combination of two of them.